How the CRB1 gene affects inherited retinal degeneration and guides gene therapy
Molecular and cellular requirements for Crb1 gene function in the onset and therapeutic rescue of an inherited retinal degeneration
Finding out which versions of the CRB1 gene in retinal cells must be present so gene replacement can stop vision loss for people with CRB1-related inherited retinal degeneration.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11237973 on NIH RePORTER |
What this research studies
From the patient's point of view, researchers are using mouse models that lack the CRB1 gene to see what goes wrong in the retina when CRB1 is missing. They remove or restore specific CRB1 isoforms (different gene versions) in particular retinal cell types and watch how the retinal structure and function change over time. The team will look for the exact cell locations and CRB1 versions that prevent damage to the outer limiting membrane and preserve vision. That information is intended to point to the best form of CRB1 to use in future gene replacement treatments.
Who could benefit from this research
Good fit: People who have inherited retinal degeneration caused by mutations in the CRB1 gene, or carriers of CRB1 variants, would be the primary group who could benefit from therapies informed by this work.
Not a fit: Patients whose vision loss is due to causes other than CRB1 mutations, or who have very late-stage retinal damage that cannot be repaired, are unlikely to benefit from CRB1-directed approaches.
Why it matters
Potential benefit: If successful, this work could identify the right CRB1 form and target cells for gene therapy that halts or prevents vision loss in people with CRB1-related retinal degeneration.
How similar studies have performed: Gene replacement has worked for some other inherited retinal diseases in animals and humans, but CRB1-specific replacement remains largely at the preclinical and exploratory stage.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Kay, Jeremy N — Duke University
- Study coordinator: Kay, Jeremy N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.